• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Advanced Energy Industries, Inc. - Common Stock
Ampd Ventures Inc
Apollo Global Management, Inc. (New) Common Stock
Benchmark Electronics, Inc. Common Stock
BlackRock Utility, Infrastructure & Power Opportunities Trust
Edgio, Inc. - Common Stock
Infobird Co., Ltd - Ordinary Shares
Jinxin Technology Holding Company - American Depositary Shares
Katapult Holdings, Inc. - Warrant
OneConstruction Group Limited - Ordinary Shares
PLAYSTUDIOS, Inc. - Warrant
Edit Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Kymera Therapeutics, Inc. - Common Stock (NQ:KYMR)

110.85 UNCHANGED
Delayed Quote Updated: 4:00 PM EDT, Oct 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 816
Open 110.85
Bid (Size) 44.96 (100)
Ask (Size) 120.00 (100)
Prev. Close 110.85
Today's Range 110.85 - 110.85
52wk Range 55.26 - 130.05
Shares Outstanding 55,307,775
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Kymera Therapeutics (KYMR) Q2 2026 Earnings Call Transcript ↗
August 12, 2026
Enrollment completed six months early; $1.5B cash runway into 2029. 
Via The Motley Fool
Topics Earnings
News headline image
Kymera Therapeutics Q2 Earnings Call Highlights ↗
August 05, 2026
Kymera Therapeutics (NASDAQ:KYMR) said it completed enrollment in its Phase 2b atopic dermatitis trial of KT-621 about six months ahead of schedule, positioning the company to report top-line data by... 
Via MarketBeat
Topics Earnings

Performance

52-Week Range 14.8% below 52-week high
110.85
55.2652W Low 130.0552W High
1 Week 4.2% below 1-week high
104.391W Low 115.751W High

Kymera Therapeutics, Inc. - Common Stock (KYMR) traded between $55.26 and $130.05 over the past 52 weeks and last traded at $110.85, 14.8% below its 52-week high. Over the past week it ranged between $104.39 and $115.75.

Past 12 Months
+5.8%
-9.2%
+0.4%
+27.2%
+52.4%
+98.7%
1W +$6.07
1M -$11.21
3M +$0.47
6M +$23.68
YTD +$38.09
1Y +$55.05

KYMR was +98.7% over the past year, +27.2% over six months, +52.4% year to date, +5.8% in the last week.

12 Months vs Market
KYMR
+98.7%
DIA
+13.3%
SPY
+14.4%
QQQ
+16.3%
IWM
+13.7%

Over the past 12 months KYMR returned +98.7% versus DIA (Dow) +13.3%, SPY (S&P 500) +14.4%, QQQ (Nasdaq 100) +16.3% and IWM (Russell 2000) +13.7%.

Volume & Liquidity 0.00× 3-mo avg
Today 816 3-mo avg 738.9K
1W
756.9K
1M
851.0K
3M
738.9K
6M
768.3K
YTD
749.8K
1Y
798.8K

KYMR most recently traded 816 shares against a 3-month average daily volume of 738.9K.

More News

Read More
News headline image
Kymera's CEO Sold $6 Million in Stock After a 170% Run ↗
July 12, 2026
Via The Motley Fool
Topics Regulatory Compliance
Kymera Therapeutics (NASDAQ:KYMR) Soars on Q1 2026 Revenue and EPS Beat ↗
April 30, 2026
Via Chartmill
Kymera Therapeutics Inc (NASDAQ:KYMR) Stock Falls 6.6% After Q4 2025 Earnings Miss and Extended Clinical Timelines ↗
February 26, 2026
Via Chartmill
Topics Earnings
News headline image
Why Kymera Therapeutics Stock Popped This Week ↗
June 26, 2026
Via The Motley Fool
These stocks are gapping in today's session ↗
June 25, 2026
Via Chartmill
News headline image
Kymera Therapeutics Stays on Track With KT-621 Trials, Teases IRF5 Data ↗
May 26, 2026
Via MarketBeat
News headline image
Boxer Capital’s $18 Million Corvus Pharma Bet Signals Confidence in This Biotech’s Next Phase ↗
May 17, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why One Healthcare Fund Increased Its Kodiak Sciences Stake Amid an Eye-Popping Rally ↗
May 17, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Vir Biotechnology Stock Has Doubled This Past Year. One Fund Just Bought 1.2 Million Shares ↗
May 17, 2026
Via The Motley Fool
News headline image
What to Know About This Fund’s $50 Million Exit From Ascendis Pharma ↗
May 14, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Fund Has a $75 Million Bet on a Hair Loss Biotech Stock Up More Than 500% Post-IPO ↗
May 14, 2026
Via The Motley Fool
Topics Initial Public Offering
News headline image
Why This Hedge Fund Added $29 Million to a Cancer Stock Already Up 700% ↗
May 14, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Nextech Trims Kymera at a Recent High — think Foolishly before acting. ↗
March 19, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Investment Firm Doubles Down on Biotech Stock, Adds 386,000 Shares, According to Recent SEC Filing ↗
March 09, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Investment Manager Loads Up on CELC Stock, Adds 135,000 Shares, According to Latest SEC Filing ↗
March 06, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Investment Firm Builds Position in TERN Stock, According to Recent SEC Filing ↗
March 05, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Investment Firm Bets Big on TNGX Stock With $9.5 Million Purchase, According to Recent SEC Filing ↗
March 04, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Kymera (KYMR) Q4 2025 Earnings Call Transcript ↗
February 26, 2026
Via The Motley Fool
Topics Earnings
News headline image
Structure Therapeutics Stock Soars Over 200% as One Fund Adds to a $242 Million Position ↗
February 25, 2026
Via The Motley Fool
News headline image
Protagonist Stock Up 120%, but One Fund Just Revealed a $170 Million Exit ↗
February 25, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Disc Medicine Stock Is Swinging, but This Fund's New $52 Million Bet Shows Conviction ↗
February 25, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Kymera Stock Up 130% as $135 Million Buy Boosts Immunology Bet ↗
February 23, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Kymera Therapeutics Stock Up 120% in 1 Year as Fund Adds $3 Million More ↗
February 17, 2026
Via The Motley Fool

Frequently Asked Questions

Is Kymera Therapeutics, Inc. - Common Stock publicly traded?
Yes, Kymera Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Kymera Therapeutics, Inc. - Common Stock trade on?
Kymera Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Kymera Therapeutics, Inc. - Common Stock?
The ticker symbol for Kymera Therapeutics, Inc. - Common Stock is KYMR on the Nasdaq Stock Market
What is the current price of Kymera Therapeutics, Inc. - Common Stock?
The current price of Kymera Therapeutics, Inc. - Common Stock is 110.85
When was Kymera Therapeutics, Inc. - Common Stock last traded?
The last trade of Kymera Therapeutics, Inc. - Common Stock was at 10/22/26 04:00 PM ET
What is the market capitalization of Kymera Therapeutics, Inc. - Common Stock?
The market capitalization of Kymera Therapeutics, Inc. - Common Stock is 6.13B
How many shares of Kymera Therapeutics, Inc. - Common Stock are outstanding?
Kymera Therapeutics, Inc. - Common Stock has 6B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap